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http://dContents lists available at ScienceDirectEditorialChronic exit-site care using povidone–iodine versus normal
saline in peritoneal dialysis patientsContinuous ambulatory peritoneal dialysis is an important
treatment method for patients with end-stage renal disease.
Although the incidence of catheter-associated complications
such as peritonitis and exit-site infection has been decreasing,
these complications have not been resolved completely. There-
fore, prevention of catheter-associated infections is essential
both soon after peritoneal dialysis (PD) catheter placement
and during long-term PD treatment. The currently used local
application materials for prophylactic exit-site care in PD
patients in Korea are povidone–iodine (92.7%), hydrogen
peroxide (4.4%), normal saline (1.2%), alcohol (0.9%), and
chlorhexidine (0.8%) (personal communication; Baxter, Gam-
bro and FMC, June 2014). The role of topical disinfectants in
long-term exit-site care remains unclear. Moreover, much
controversy surrounds the prophylactic strategies used to
prevent such infections.
Several reports indicated lower incidence rates of exit-site
infection with the use of povidone–iodine than with other
cleansing methods in PD patients. Luzar et al [1] reported that,
in a large randomized trial, a nonocclusive dressing plus
povidone–iodine was found to be associated with a lower rate
of exit-site infection than soap and water alone (0.27 vs. 0.71
episodes/patient-year). In addition, in a nationwide survey for
exit-site care in Austria, disinfectants for chronic exit-site care
included povidone–iodine (n¼155), sodium hypochlorite
(n¼31), povidone–iodine plus sodium hypochlorite (n¼102),
and octenidine dihydrochloride/phenoxyethanol (n¼17). In
this randomized controlled trial, local application of povi-
done–iodine solution at the exit-site signiﬁcantly reduced
the rate of exit-site infections, compared with local treatment
with water and a nondisinfectant soap [2].
Grosman et al [3] reported that the alternative cleansing
agent 50% Amuchina (electrolytic chloroxidizer) was more
effective than 10% povidone–iodine and as effective as 4%
chlorhexidine, but with fewer adverse secondary effects.
Patients using 3% Amuchina presented an exit-site infection
rate similar to that in patients using 50% Amuchina. No adverse
secondary effects were observed with the use of Amuchina at
either concentration. The cost of 3% Amuchina was signiﬁcantly
lower than that of the 50% concentration, and it was even lower
than the cost for 10% povidone–iodine or 4% chlorhexidine.
In the literature, no consensus has been reached regarding
the prophylactic use of povidone–iodine or other antiseptics at32/$ - see front matter & 2014. The Korean Society of Nephrology. Publi
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
x.doi.org/10.1016/j.krcp.2014.07.005the exit-site in all patients. However, povidone–iodine is still
the most popular antiseptic material for prophylactic use and
for treating exit-site care in patients undergoing PD world-
wide. Polyurethane catheters can be damaged by long-term
exposure to povidone–iodine but not silicon catheters.
Allergic dermatitis around the catheter exit-site, caused by
topical antiseptics such as povidone–iodine and chlorhexidine
gluconate, is an uncommon complication in patients under-
going long-term PD. The frequency of this type of dermatitis is
not known because reports of isolated cases constitute the
only source of information [4]. Allergic dermatitis around the
catheter exit-site, including anaphylaxis, caused by povidone–
iodine is increasingly reported as a complication. Antiseptic
solutions should be used cautiously in such patients. Although
the irritation induced by the local application of povidone–
iodine can lead, although infrequently, to secondary exit-site
infection, this is the most common reason for patients to stop
using povidone–iodine. In particular, Yavascan et al [4]
reported that the povidone–iodine group had signiﬁcantly
higher rates of exit-site infection, but showed no difference
in the risk of peritonitis and the number of removed catheters
compared with the normal saline group. In this study, 98
patients treated with either povidone–iodine or normal saline
were included. For Group 1 (34 patients), povidone–iodine was
used, and for Group 2 (64 patients), the exit-site was simply
cleaned with normal saline (0.9% NaCl). The frequency of exit-
site infection was signiﬁcantly higher in Group 1 (povidone–
iodine) than in Group 2. Therefore in this study, exit-site care
with normal saline was an effective strategy for reducing the
incidence of exit-site infection in children undergoing long-
term PD. However, the mechanism by which normal saline
protects against exit-site infection remains unclear [5].
In the current issue of Kidney Research and Clinical Practice,
Lee et al [6] compared the effectiveness of normal saline and
povidone–iodine for chronic exit-site care in terms of reducing
the incidence of exit-site infection and peritonitis in PD
patients. They changed the exit-site care method gradually
from povidone–iodine to normal saline in September 2007,
and almost all patients were treated with saline by December
2007. In their study, they found that exit-site infection and
peritonitis were not signiﬁcantly associated with the methods
of dressing, but the incidences of adverse effects such as skin
irritation and itching were signiﬁcantly lower in patientsshed by Elsevier. This is an open access article under the CC BY-NC-ND
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povidone–iodine. However, they also did not explain the
effectiveness of normal saline in preventing exit-site infection.
On the basis of the results of the current study, it may be
difﬁcult to conclude that normal saline was a safer and more
effective topical antiseptic than povidone–iodine. This study
had some limitations such as the retrospective analysis, a small
number of patients, exclusion of recurrent events of exit-site
infection, and uncontrolled prophylactic antibiotics, including
the topical application of mupirocin or gentamicin. The inci-
dence of events may have been under-reported. Furthermore,
from September 2007 to December 2007, the exit-site care
method was changed from povidone–iodine to normal saline.
During this period, it is unclear which disinfectant was
associated with catheter-related infections.
In the literature, the mechanism by which normal saline
protected against exit-site infection is unclear. Mechanical
removal of resident bacteria and debris from an uninfected
exit-site using a cleansing swab, regardless of povidone–iodine
or normal saline content, may be enough to promote healthy
re-epithelialization at the exit-site. However, the application of
povidone–iodine may resolve signs of inﬂammation. Prevent-
ing mechanical injury in the re-epithelialized exit site is the
most important strategy to maintain a healthy exit site,
regardless of the use of povidone–iodine or normal saline as
topical applicants. Besides catheter immobilization, avoiding
irritation-inducing antiseptics such as povidone–iodine during
the break-in period is important to maintain a healthy exit site
during long-term PD. The European best practice guidelines
emphasize that povidone–iodine preparations and hydrogen
peroxide should be avoided due to epithelial toxicity, espe-
cially during the early healing phase immediately after cathe-
ter implantation [7]. Amuchina may be considered an
alternative antiseptic for the ﬁrst postimplantation care of
the exit site.
In conclusion, the work of Lee et al [6] compared the
usefulness of normal saline for uninfected exit-site care with
that of povidone–iodine. No signiﬁcant differences in the
incidences of exit-site infection and peritonitis were observed
between the two methods of dressing, but the incidences of
adverse effects such as skin irritation and itching were lower
in the normal saline group than in the povidone–iodine group.
Therefore, normal saline may be an alternative treatment
agent for exit-site care in PD patients, especially in children.
Two options are available for stable exit-site care in PD
patients. First, povidone–iodine can be used for exit-site care
as a routine method, unless allergic dermatitis develops.
Normal saline can be used as a substitute in case a povi-
done–iodine-induced skin reaction occurs. Symptoms usually
subside within 1 week after the initiation of daily topical
application of normal saline solution. Alternatively, dressing
with normal saline can be applied with routine exit-site care
without signs of infection. If an exit-site infection is suspected,the method of dressing should be changed temporarily from
normal saline to povidone–iodine until the signs of infection
are eliminated. Topical application of normal saline could be
an alternative method of prophylactic exit-site care for long-
term PD patients who have uninfected, stabilized exit-sites but
allergic skin reactions.Conﬂict of interest
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